MedTrace Logo

Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+

NCT03121313 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2019-02-12

No results posted yet for this study

Summary

Primary Objective:

To determine the 2-year distant failure rate of maintenance tegafur-uracil in patients with squamous cell carcinoma of oral cavity with extracapsular spreading of lymph nodes.

Secondary Objectives:

* To determine the 2-year locoregional failure rate.
* To evaluate the 2-year overall survival (OS) rate.
* To evaluate the 2-year progression-free survival (PFS) rate.
* To assess the safety profiles.

Conditions

  • Squamous Cell Carcinoma of Oral Cavity

Interventions

DRUG

tegafur-uracil

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Hung-Ming Wang, M.D. · Chang Gung Medical Foundation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-26
Primary Completion
2020-05-11
Completion
2020-05-11

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03121313 on ClinicalTrials.gov